Insurance Megamergers: How Will They Impact Manufacturers’ Commercialization Strategy?

Commercialization and HEOR, Life Sciences, Pharma Manufacturing and Supply Chain, Pharmaceutical,
  • October 15, 2015

There’s merger frenzy going on these days with some of the largest health insurers in the industry. With partnerships like Aetna + Humana and Anthem + Cigna on the horizon, the question is – what will it mean for manufacturers? How will the creation of these mega-entities impact your commercialization plans, pricing, reimbursement and access strategy, and ultimately, your Brand’s success?

Join Xcenda’s Cathy Carroll, Senior Director, Managed Markets/Market Access and former AMCP president, along with Nina Ohara, Director in Commercial Consulting, to discuss these and other pertinent questions impacting your business. This complimentary webinar will explore what’s happening in the payer space today, the impetus for this change, and the potential outlook of the health insurance landscape in the future. Manufacturers will benefit by staying on top of these shifts and considering the impact it may have on their market access strategy.

During this session, we will address:

  • Shift from fee-for-service to value-based models
  • Increased demand to demonstrate value and quality of care given a heightened interest in population health management
  • Effective execution of FDAMA 114

Speakers

Cathy Carroll, PhD, MA, MBA, BSPharm, Senior Director of Managed Markets/Market Access, Commercial Consulting, Xcenda

Cathy Carroll, PhD, MA, MBA, BSPharm, is a Senior Director of Managed Markets/Market Access for Commercial Consulting for Xcenda. Dr. Carroll’s team provides strategic insights into the development of evidence-based value propositions in support of pricing, reimbursement, and access strategies by Pharmaceutical, biotech, and medical device companies within and external to the United States.

Prior to joining Xcenda, Dr. Carroll was a member of the Global Health Economic and Outcomes Research (HEOR) and Evidence Based Medicine group for a leading Pharmaceutical manufacturer. Prior to her work guiding data generation and design of global market access strategies, she directed data generation and value proposition development for the markets within the United States.

Dr. Carroll’s career has primarily focused on Pharmacy and Therapeutic (P&T) deliberations, formulary decision making, and mentorship of young professionals. She has directed P&T activities within commercial health plans, a managed Medicaid health plan, as a consultant to the pharmacy benefit management (PBM) industry, and within the acute inpatient setting. Beyond her role in formulary placement, Dr. Carroll has extensive research experience. She was the Director of Patient Care Services within a large Midwestern integrated delivery system. She has also mentored young professionals and aspiring researchers during (and after) her tenure at the University of Missouri-Kansas City where she held a triple appointment in the School of Pharmacy, Department of Economics, and the Bloch School of Management. Her research endeavors have resulted in numerous peer-reviewed articles and book chapters in the areas of quality improvement, cost-effectiveness analysis, as well as humanistic and economic outcomes.

Dr. Carroll is a member of the Academy of Managed Care Pharmacy (AMCP) and the International Society of Pharmacoeconomic and Outcomes Research (ISPOR). Her contributions to AMCP included participation with numerous committees in addition to service when elected by the membership to serve the Academy as Treasurer, President, and member of both the Board of Directors for AMCP and the Board of Trustees for the AMCP Foundation.

Dr. Carroll received her Doctorate of Philosophy and a Master’s degree in Administration from the Department of Economics at the University of Kansas. She received her Master in Business Administration and Bachelor of Science in Pharmacy from the University of Missouri-Kansas City’s Henry W. Bloch School of Management and the School of Pharmacy, respectively.

Nina Ohara, PharmD, MBA, MS, RPh, Director, Commercial Client Strategy Team, Xcenda

Nina Ohara, PharmD, MBA, MS, RPh is a Director with the Commercial Client Strategy Team at Xcenda where she helps clients achieve their commercialization goals and objectives. Dr. Ohara works with a multitude of manufacturers to capitalize on Brand and Market Access opportunities.

Dr. Ohara brings to Xcenda over 15 years of experience from managed care, Pharmaceutical and biotechnology industry. She has shaped market access strategies for multiple Brands throughout all phases of the product lifecycle. Most recently, Dr. Ohara was on a Brand Marketing team where she drove commercial success of a mature Brand by executing innovative patient and provider programs. Prior to that experience, Dr. Ohara led several product launches to maximize reimbursement and access in the specialty market. She had gained payer access goals ahead of Wall Street expectations for a product launch by communicating a strong payer value proposition story and seamlessly executing account management team training, tactics and metrics. In addition, she has enhanced provider reimbursement programs and collaborated closely with field provider reimbursement teams on strategy, messaging and tactics. She has also been instrumental in pre-launch efforts to help construct clinical and health outcomes programs to lay the foundation for commercial success. Prior to her Pharmaceutical and biotechnology industry experience, Dr. Ohara worked in managed care in hospital contracting, and health management programs.

Dr. Ohara earned her Doctorate of Pharmacy from University of Southern California (USC) Pharmacy School and her Masters of Business Administration from USC Marshall School of Business. She also received her Masters of Science and Bachelor of Science in Biochemistry at University of California, Los Angeles (UCLA).

Who Should Attend?

This event will have wide appeal to individuals working for pharmaceutical, biotech, and medical devices companies. This includes professionals in:

  • Brand Management
  • Managed Markets
  • Market Access
  • Commercialization Team
  • Health Policy
  • Channel Management
  • Organized Customer Group Marketing

Xtalks Partners

Xcenda

Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. We support global Pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, Xcenda helps manufacturers identify, demonstrate, and deliver their brand’s value proposition to key healthcare stakeholders.

Xcenda is backed by an even wider breadth of healthcare knowledge and partnerships through AmerisourceBergen Corporation (NYSE: ABC), one of the world’s largest Pharmaceutical services companies. Xcenda’s strategic consulting services support the design of patient support services and specialty distribution programs to improve product access and adherence at every stage of its life cycle.

Media Partners

Related Webinars

Sign Up or Login To Register for this Webinar

Interested in this webinar? Sign up to register for any upcoming or recorded webinar or if you’re already a member Login.

Sign Up